Hubungan Subtipe Molekuler dengan Densitas Tumor Infiltrating Lymphocytes Stroma pada Karsinoma Lobular Invasif Payudara

Hasnaini Hasnaini, Aswiyanti Asri, Henny Mulyani

Abstract


Pendahuluan: Karsinoma lobular invasif payudara merupakan karsinoma invasif payudara terbanyak ke dua dengan insiden mencapai hingga 15% dari seluruh karsinoma invasif payudara. Tumor Infiltrating Lymphocytes (TIL) adalah suatu respon imun tubuh dalam melawan pertumbuhan dan perkembangan tumor. Penilaian TIL stroma adalah suatu faktor prognostik karsinoma invasif payudara dan dihubungkan dengan luaran yang baik pada subtipe tripel negatif dan HER-2. Tujuan penelitian: Untuk mengetahui karakteristik karsinoma lobular invasif dan untuk menganalisis hubungan subtipe molekuler dengan densitas TIL. Metode: Penelitian ini adalah penelitian observasional dengan pendekatan cross sectional. Sampel karsinoma lobular invasif dari 3 laboratorium Patologi Anatomik di Padang sebanyak 30 kasus. Densitas TIL dinilai berdasarkan rekomendasi The International TILs Working Group, kemudian dikelompokkan rendah, intermediet, dan tinggi. Dilakukan pulasan imunohistokimia (IHK) ER, PR, HER-2 dan Ki67 untuk menentukan subtipe molekuler yaitu luminal A, luminal B, HER-2 positif dan tripel negatif. Analisis bivariat menggunakan uji Chi Square dengan nilai p<0,05 dianggap bermakna. Hasil: Sebagian besar karsinoma lobular invasif dengan densitas TIL rendah (70%), dengan subtipe molekuler terbanyak adalah luminal A. Analisis bivariat menunjukan densitas TIL rendah banyak pada luminal A, dan densitas TIL intermediet banyak pada luminal B. Analisis statistik menunjukkan hubungan yang bermakna antara subtipe molekuler dengan densitas TIL dengan nilai p=0,004. Kesimpulan: penelitian ini menunjukkan adanya hubungan bermakna antara subtipe molekuler dengan densitas TIL pada karsinoma lobular invasif.


Keywords


kanker payudara, lobular, TIL, subtipe molekuler

Full Text:

PDF

References


. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

. GLOBOCAN 2020. Breast. Accessed July 22, 2021. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf

. Indra. Peringatan hari kanker sedunia. Published 2020. https://dinkes.sumbarprov.go.id/details/news/470

. World Health Organization of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

. Desmedt C, Salgado R, Fornili M, et al. Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst. 2018;110(7):768-776. doi:10.1093/jnci/djx268

. Tille J-C, Vieira AF, Saint-Martin C, et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol. Published online 2020. doi:10.1038/s41379-020-0561-9

. Oner G, Altintas S, Canturk Z, et al. The immunologic aspects in hormone receptor positive breast cancer. Cancer Treat Res Commun. 2020;25(August):1-6. doi:10.1016/j.ctarc.2020.100207

. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-271. doi:10.1093/annonc/mdu450

. Hida AI, Ohi Y. Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. Ann Oncol. 2015;26(11):2351-2358. doi:10.1093/annonc/mdv363

. Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. Breast Dis. 2020 (1-9)

. Dossus L, Benusiglio PR. Lobular breast cancer: Incidence and genetic and non-genetic risk factors. Breast Cancer Res. 2015;17(1):1-8. doi:10.1186/s13058-015-0546-7

. Ahn SG, Cha YJ, Bae SJ, Yoon C, Lee HW, Jeong J. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. BMC Cancer. 2018;18(1):1-9. doi:10.1186/s12885-018-4228-6

. Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer. Breast Cancer Res Treat. 2020;183(2):347-354. doi:10.1007/s10549-020-05771-7

. Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: The prognostic impact of histopathological grade, E-cadherin and molecular subtypes. Histopathology. 2015;66(3):409-419. doi:10.1111/his.12572

. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021.

. Reed MA, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: Morphology, biomarkers and ’omics. Breast Cancer Res. 2015;17(1):1-11. doi:10.1186/s13058-015-0519-x

. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550. doi:10.1093/annonc/mdu112

. Annaratone L, Cascardi E, Vissio E, et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology. 2020;87:125-142. doi:10.1159/000507055

. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(59):1-7. doi:10.1186/s40425-016-0165-6

. Dushyanthen S, Beavis PA, Savas P, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13(1):1-13. doi:10.1186/s12916-015-0431-3




DOI: https://doi.org/10.33854/heme.v5i1.1145

Refbacks

  • There are currently no refbacks.


Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.